Drugs / KN056
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05385575 | Aug 2022 → Dec 2023 | type 2 diabetes mellitus | Suzhou Alphamab Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05385575 ↗ |
| Modality | Protein / enzyme biologic | “It is a recombinant human Fc-fused GLP-1 variant protein.” NCT05385575 ↗ |
| Route | Subcutaneous | “The dose will be given as a subcutaneous (SC) injection into the abdomen.” NCT05385575 ↗ |